SCHEMBL2747458

SCHEMBL2747458

CC(C)c1ccc(S(=O)(=O)Nc2ccsc2C(=O)O)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 1/20 0.64
TSHR P16473 2/20 0.55
LMNA P02545 1/20 0.55
HPGD P15428 1/20 0.55
CCR2 P41597 1/20 0.47
KEAP1 Q14145 2/20 0.47
NFE2L2 Q16236 2/20 0.47
POLB P06746 2/20 0.47
CASP6 P55212 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
MAPT P10636 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.45
RAB9A P51151 1/20 0.45
NRP1 O14786 1/20 0.44
CCR9 P51686 1/20 0.44
MCL1 Q07820 1/20 0.44
APEX1 P27695 1/20 0.44
RECQL P46063 1/20 0.44
CTDSP1 Q9GZU7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2748117 0.88 ACLY (0.56) ACLYTSHRLMNAHPGDPOLB
SCHEMBL2748676 0.87 HPGD (0.74) ACLYTSHRLMNAHPGDCCR2
SCHEMBL492007 0.85 ACLY (0.77) ACLYTSHRLMNAHPGDCCR2
SCHEMBL1200176 0.85 ACLY (0.64) ACLYTSHRLMNAHPGDKEAP1
Hydrochloric Acid SCHEMBL492324 0.83 ACLY (0.75) ACLYTSHRLMNAHPGDCCR2
SCHEMBL532975 0.83 ACLY (0.69) ACLYTSHRLMNAHPGDMEN1
SCHEMBL7530793 0.82 LMNA (0.80) ACLYTSHRLMNAHPGDKEAP1
SCHEMBL2747434 0.82 ACLY (0.64) ACLYTSHRLMNAHPGDPOLB
Hydrochloric Acid SCHEMBL533067 0.81 ACLY (0.68) ACLYTSHRLMNAHPGDMEN1
SCHEMBL2747439 0.81 ACLY (0.60) ACLYTSHRLMNAHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178699-B2 Modulators of CCR9 receptor and methods of use thereof PFIZER INC. (US) 2012-05-15 US disclosed
US-8178699-B2 Modulators of CCR9 receptor and methods of use thereof PFIZER INC. (US) 2012-05-15 US disclosed
US-8178699-B2 Modulators of CCR9 receptor and methods of use thereof PFIZER INC. (US) 2012-05-15 US disclosed
US-20100029753-A1 MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. 2010-02-04 US disclosed
US-20100029753-A1 MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. 2010-02-04 US disclosed
US-20100029753-A1 MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF ENCYSIVE PHARMACEUTICALS, INC. 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100029753-A1 MODULATORS OF CCR9 RECEPTOR AND METHODS OF USE THEREOF CCR9, CCR1, CCR4 ACLY 4546/4885TSHR 957/4885LMNA 3295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.